Therapeutic Potential of Gut Microbiota in Colorectal Cancer

سال انتشار: 1401
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 69

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

MEDISM23_308

تاریخ نمایه سازی: 16 مهر 1401

چکیده مقاله:

Background and Aim : The numerous bacteria, fungi, protozoa, and viruses are associated withgut microbiota diversity and obviously, the gut microbiota's composition has strongly impactedthe development of colorectal cancer (CRC). Bacteria, among gut microbiota's composition,provide metabolites with antioxidant and anti-inflammatory properties which is modulated thehost’s and gut’s homeostasis. Aside from gene mutation and hereditary variables, the loss of gutmicro-ecological equilibrium offers a novel approach to treating CRC.Methods : We searched the keywords "Gut microbiota," "Colorectal cancer," and "Treatment" inPubMed, NCBI, Scopus, and Google Scholar for updated articles.Results : Modulating gut microbiota composition has been recently discussed as a promisingtechnique for improving tumor response to chemotherapy drugs. Meanwhile, the elimination ofgut microbiota provides clinical advantages to CRC patients by overcoming chemotherapyresistance. The gut microbiota, especially intratumor bacteria, contribute to inducing gemcitabineresistance through enzymatic inactivation of the medication. In contrast, a gemcitabineciprofloxacincombination therapy reverses resistance. Indeed the impact of gut microbiota'smakeup and activity have demonstrated the improvement of colorectal carcinogenesis treatmentand anticancer therapy's efficacy. CRC-associated pathogens are known as a possible colorectalcancer screening tool due to gut microbiota development. The fecal microbiota can use to createnon-invasive colorectal cancer indicators. Also, the gut microbiota has been shown to impactchemotherapy and immunotherapy effectiveness by influencing immunity. Cyclophosphamide,used in chemotherapy and immunotherapy, has been demonstrated to trigger the translocation ofspecific Gram-positive bacteria (Lactobacillus johnsonii, Lactobacillus murinus, and Enterococcushirae) into secondary lymphoid organs.Conclusion : Little information is available on the microbiome that affects tumor regression orresistance to cancer treatment; Because intestinal microbiota is still a new field in treating CRC,and more research is needed. On the other hand, we found that controlling the gut microbiotapopulation positively affects CRC. So it is better to focus on the relationship between gutmicrobiota and immunotherapy or chemotherapy.

نویسندگان

Morteza Hassandokht Mashhadi

Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran

Negin Najmi Noghondar

Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran

Sepideh Hassanzadeh

Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran - . Antimicrobial Resistance Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran - . Department of Microbiology and virology, School of